Fintepla (Fenfluramine HCl) Patent Expiration, LOE Window & CMS Spending

Fintepla (Fenfluramine HCl) by Ucb: FDA Orange Book core substance LOE 2037-06-20 (last listed 2038-12-29), 0 AB generics, $230.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN212102 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-06-20
Last Listed Patent or Exclusivity Date2038-12-29
Orange Book Patents (*PED Extensions)27 patents (14 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$230.7M
2024 Medicare Part D Spend$40.9M
2024 Medicaid Spend$189.8M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.